Guidance to sponsors on how to manage clinical trials during the COVID-19 pandemic

The impact of the pandemic on European health systems and more broadly on society, will make it necessary for sponsors to adjust how they manage clinical trials and the people who participate in these trials. The guidance provides concrete information on changes and protocol deviations that may be needed in the conduct of clinical trials to deal with extraordinary situations and includes a harmonised set of recommendations.

You could find the Guidance here

Source: European Medicines Agency (EMA)